← Back to Patent Explorer
US4530838A Expired / Lapsed US ⏱️ 0.0 years remaining

Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals

Assignee: Salk Institute for Biological Studies
•
Filing: 1983-07-08
•
Granted: 1985-07-23
•
Expires: 2003-07-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract CGRP (calcitonin-gene-related peptide) has the formula: ##STR1## A related peptide has the residue Lys instead of Glu in the 35-position. CGRP or this homolog or pharmaceutically acceptable salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, including humans, to influence memory, mood and pain appreciation and to achieve a substantial lowering of blood pressure or gastric acid secretion over an extended period of time. They also may be administered to affect ingestion behavior, taste and sensory perception.

Inventors

  • 👤 Ronald M. Evans
  • 👤 Larry Swanson
  • 👤 Wylie W. Vale, Jr.
  • 👤 Michael G. Rosenfeld
  • 👤 Susan G. Amara
  • 👤 Marvin R. Brown
  • 👤 Jean E. F. Rivier

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 15:13
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57527; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 25 words
A substantially pure synthetic peptide, or a nontoxic addition salt of a synthetic peptide, having the formula: ##STR8## wherein R 35 is Glu or Lys.
Claim 2
Dependent Claim 25 words
A substantially pure synthetic peptide, or a nontoxic addition salt of a synthetic peptide, having the formula: ##STR8## wherein R 35 is Glu or Lys.
Claim 3
Dependent Claim 10 words
The peptide of claim 1 wherein R 35 is Glu.
Claim 4
Dependent Claim 10 words
The peptide of claim 1 wherein R 35 is Lys.
Claim 5
Dependent Claim 48 words
A pharmaceutical composition for lowering blood pressure or gastric acid secretion in mammals comprising an effective amount of a substantially pure peptide, or a nontoxic addition salt thereof, having the formula: ##STR9## wherein R 35 is Glu or Lys; and a pharmaceutically acceptable liquid or solid carrier therefor.
Claim 6
Dependent Claim 48 words
A pharmaceutical composition for lowering blood pressure or gastric acid secretion in mammals comprising an effective amount of a substantially pure peptide, or a nontoxic addition salt thereof, having the formula: ##STR9## wherein R 35 is Glu or Lys; and a pharmaceutically acceptable liquid or solid carrier therefor.
Claim 7
Dependent Claim 10 words
The composition of claim 4 wherein R 35 is Glu.
Claim 8
Dependent Claim 10 words
The composition of claim 4 wherein R 35 is Lys.
Claim 9
Independent Claim 46 words
A method for lowering the blood pressure or gastric acid secretion of a mammal, which method comprises administering to said mammal an effective amount of a substantially pure peptide, or a nontoxic addition salt thereof, having the formula: ##STR10## wherein R 35 is Gly or Lys.
Claim 10
Independent Claim 46 words
A method for lowering the blood pressure or gastric acid secretion of a mammal, which method comprises administering to said mammal an effective amount of a substantially pure peptide, or a nontoxic addition salt thereof, having the formula: ##STR10## wherein R 35 is Gly or Lys.
Claim 11
Dependent Claim 21 words
The method in accordance with claim 7 wherein said administering is carried out either orally, intravenously, subcutaneously, percutaneously, intracerebrospinally or intramuscularly.
Claim 12
Dependent Claim 25 words
The method of claim 7 wherein said administration is at a level of between about 1 and about 200 micrograms per Kg. of body weight.
Claim 13
Dependent Claim 10 words
The method of claim 7 wherein R 35 is Glu.
Claim 14
Dependent Claim 10 words
The method of claim 7 wherein R 35 is Lys.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-07-22 1989-01-21 1989-07-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-07-22 1993-01-21 1993-07-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-07-22 1997-01-21 1997-07-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag